Skip to main content
padlock icon - secure page this page is secure

Revisiting De Novo Drug Design: Receptor Based Pharmacophore Screening

Buy Article:

$68.00 + tax (Refund Policy)

De novo drug design methods such as receptor or protein based pharmacophore modeling present a unique opportunity to generate novel ligands by employing the potential binding sites even when no explicit ligand information is known for a particular target. Recent developments in molecular modeling programs have enhanced the ability of early programs such as LUDI or Pocket that not only identify the key interactions or hot spots at the suspected binding site, but also and convert these hot spots into three-dimensional search queries and virtual screening of the property filtered synthetic libraries. Together with molecular docking studies and consensus scoring schemes they would enrich the lead identification processes. In this review, we discuss the ligand and receptor based de novo drug design approaches with selected examples.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 3D-QSAR; analog based drug design; consensus scoring; de novo drug design; fragment based drug design; pharmacophore; receptor based pharmacophore

Document Type: Research Article

Publication date: August 1, 2014

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more